Related Experiment Video

Updated: May 11, 2026

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach
07:06

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach

Published on: December 1, 2011

A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients

Naïm Bouazza1, Jean-Marc Tréluyer, Philippe Msellati

  • 1Université Paris Descartes, Sorbonne Paris, France. naim.bouazza@cch.aphp.fr

AIDS (London, England)
|May 31, 2013
PubMed

Insights

A new dynamic model predicts HIV progression in children using a composite inhibition score for efavirenz, didanosine, and lamivudine. This score effectively predicts treatment failure in multidrug therapy.

Area of Science:

  • Pediatric infectious diseases
  • HIV/AIDS treatment
  • Pharmacodynamics and pharmacokinetics

Background:

  • Human Immunodeficiency Virus (HIV) infection remains a significant global health challenge, particularly in children.
  • Effective antiretroviral therapy (ART) is crucial for managing HIV, but predicting treatment outcomes in pediatric populations requires sophisticated models.
  • Understanding the individual and combined effects of drugs in multidrug regimens is essential for optimizing treatment strategies.

Purpose of the Study:

  • To develop a dynamic model for predicting viral load and CD4+ T-cell count evolution in children with HIV.
  • To assess the relative contribution of each drug (efavirenz, didanosine, lamivudine) in a combination therapy.
  • To establish a composite inhibition score as a predictor of treatment failure in pediatric HIV multidrug therapy.

Main Methods:

  • An open-label, phase II clinical trial (BURKINAME - ANRS 12103) involving 49 children (2.5–15 years) receiving daily efavirenz, didanosine, and lamivudine.
  • Development of a composite inhibition score integrating the effects of each drug based on their mechanisms of action.
  • Statistical analysis to compare the predictive value of the composite score versus individual drug concentrations for treatment failure.

Main Results:

  • Efavirenz demonstrated the highest potency (65% of total effect), followed by didanosine (23%) and lamivudine (12%).
  • Pharmacokinetic targets were suggested: EC90 for efavirenz (3.3 mg/L) and AUC90 for lamivudine (8.4 mg*h/L) and didanosine (1.5 mg*h/L).
  • The composite inhibition score was a superior predictor of virologic failure compared to individual drug concentrations (HR 0.6; 95% CI 0.41-0.88).

Conclusions:

  • The study successfully assessed the contributions of efavirenz, didanosine, and lamivudine on viral load and CD4+ T-cell kinetics in HIV-infected children.
  • Pharmacokinetic targets for lamivudine and didanosine were proposed.
  • A composite inhibition score was validated as a strong predictor of treatment failure in pediatric HIV multidrug therapy.
Abstract

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).